Cargando…

The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration—A cost-effectiveness analysis from a societal perspective

BACKGROUND: The discussion on the use of bevacizumab is still ongoing and often doctors are deterred from using bevacizumab due to legal or political issues. Bevacizumab is an effective, safe and inexpensive treatment option for neovascular age-related macular degeneration (AMD), albeit unregistered...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Asten, Freekje, Michels, Charlotte T. J., Hoyng, Carel B., van der Wilt, Gert Jan, Klevering, B. Jeroen, Rovers, Maroeska M., Grutters, Janneke P. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5957378/ https://www.ncbi.nlm.nih.gov/pubmed/29772018 http://dx.doi.org/10.1371/journal.pone.0197670

Ejemplares similares

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB
por: Avery, Robert L., et al.
Publicado: (2017)

Hyperreflective foci on optical coherence tomography associate with treatment outcome for anti-VEGF in patients with diabetic macular edema
por: Schreur, Vivian, et al.
Publicado: (2018)

Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life
por: Schmid, Martin K., et al.
Publicado: (2015)

Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells
por: Chae, Jae-Byoung, et al.
Publicado: (2018)

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
por: Lim, Laurence S, et al.
Publicado: (2015)

Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions
por: Giannos, Steven A., et al.
Publicado: (2018)

Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
por: Pennington, Becky, et al.
Publicado: (2021)

Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling
por: Grutters, Janneke P.C., et al.
Publicado: (2019)

Comparing the effectiveness and costs of Bevacizumab to Ranibizumab in patients with Diabetic Macular Edema: a randomized clinical trial (the BRDME study)
por: Schauwvlieghe, A.M.E., et al.
Publicado: (2015)

Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
por: Pennington, Becky, et al.
Publicado: (2021)

Exploratory, Participatory and Iterative Assessment of Value: A Response to Recent Commentaries
por: Grutters, Janneke P.C., et al.
Publicado: (2020)

Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context
por: Schmid, Martin K., et al.
Publicado: (2018)

A genetic variant in NRP1 is associated with worse response to ranibizumab treatment in neovascular age-related macular degeneration
por: Lorés-Motta, Laura, et al.
Publicado: (2016)

Understanding the Costs of Surgery: A Bottom-Up Cost Analysis of Both a Hybrid Operating Room and Conventional Operating Room
por: Patel, Sejal, et al.
Publicado: (2020)

Hydrodynamic Radii of Ranibizumab, Aflibercept and Bevacizumab Measured by Time-Resolved Phosphorescence Anisotropy
por: Hirvonen, Liisa M., et al.
Publicado: (2016)

Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
por: Waizel, Maria, et al.
Publicado: (2017)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021)

Visual Rehabilitation in Chronic Cerebral Blindness: A Randomized Controlled Crossover Study
por: Elshout, Joris A., et al.
Publicado: (2016)

Risk factors for development and progression of diabetic retinopathy in Dutch patients with type 1 diabetes mellitus
por: Schreur, Vivian, et al.
Publicado: (2018)

Identifying the Conditions for Cost-Effective Minimally Invasive Neurosurgery in Spontaneous Supratentorial Intracerebral Hemorrhage
por: Schreuder, Floris H. B. M., et al.
Publicado: (2022)

In search of the most cost‐effective monitoring strategy for vestibular schwannoma: A decision analytical modelling study
por: Scholte, Mirre, et al.
Publicado: (2019)

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
por: Avery, Robert L, et al.
Publicado: (2014)

The outcomes of aflibercept therapy in patients with age-related macular degeneration resistant to bevacizumab or ranibizumab
por: Unsal, Erkan, et al.
Publicado: (2018)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa, Bernardete, et al.
Publicado: (2021)

Cost-effectiveness analysis of ranibizumab for retinal vein occlusion patients in China from the societal perspective
por: Ni, Weiyi, et al.
Publicado: (2021)

Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis
por: Hernandez, Luis, et al.
Publicado: (2018)

Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis
por: Yu, Justin S, et al.
Publicado: (2021)

Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture
por: Malik, Deepika, et al.
Publicado: (2014)

Antiproliferative, Apoptotic, and Autophagic Activity of Ranibizumab, Bevacizumab, Pegaptanib, and Aflibercept on Fibroblasts: Implication for Choroidal Neovascularization
por: Lytvynchuk, Lyubomyr, et al.
Publicado: (2015)

Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema
por: Alsaedi, Nasser G, et al.
Publicado: (2021)

Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
por: Jung, Byung Ju, et al.
Publicado: (2019)

Evaluation of Aflibercept Treatment Responses in Eyes with Bevacizumab/Ranibizumab-resistant Wet Age-related Macular Degeneration
por: Topal, Tuncay, et al.
Publicado: (2017)

Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema
por: Kourlaba, Georgia, et al.
Publicado: (2016)

Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study)
por: Gascon, Pierre, et al.
Publicado: (2021)

Effects of a Single Intravitreal Injection of Aflibercept and Ranibizumab on Glomeruli of Monkeys
por: Tschulakow, Alexander, et al.
Publicado: (2014)

Aflibercept in branch retinal vein occlusion as second line therapy: clinical outcome 12 months after changing treatment from bevacizumab/ranibizumab—a pilot study
por: Wirth, Magdalena A., et al.
Publicado: (2016)

How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview
por: Empeslidis, Theodoros, et al.
Publicado: (2019)

Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: A UK Healthcare Perspective
por: Adedokun, Lola, et al.
Publicado: (2016)

Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective
por: Régnier, Stephane A, et al.
Publicado: (2015)

Assessment of mouse VEGF neutralization by ranibizumab and aflibercept
por: Ichiyama, Yusuke, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h9k2o0ea645hqodsqe8u3smb0e